Early Engagement Is Good. Continuous Engagement Is Better.

Bristol Myers Squibb recently published a white paper on early patient engagement in drug development. At its core is a simple but important idea: patients, caregivers, and advocacy organizations should be involved before key decisions are made, not after. The paper argues that lived experience should help shape development strategy, trial design, recruitment approaches, communications, and…